News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
134 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17535)
Month
January (2946)
February (2976)
March (2714)
April (2913)
May (3639)
June (2347)
Day
2 (13)
3 (112)
4 (147)
5 (162)
6 (150)
7 (96)
9 (24)
10 (101)
11 (117)
12 (134)
13 (125)
14 (151)
17 (94)
18 (131)
19 (209)
20 (171)
21 (97)
24 (160)
25 (183)
26 (291)
27 (214)
28 (94)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
Day
2
3
4
5
6
7
9
10
11
12
13
14
17
18
19
20
21
24
25
26
27
28
Infectious disease
Anticipating Approval, Gilead Gears Up for Mid-Year Launch for Lenacapavir PrEP
Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.
February 12, 2025
·
2 min read
·
Tristan Manalac
Funding
Abcuro Secures $200 Million Series C to Push Rare Muscle Disease Treatment
The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion body myositis through clinical trials. Now, Abcuro is eyeing a regulatory submission and potential launch.
February 12, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
February 12, 2025
·
11 min read
Press Releases
EvolveImmune Appoints Kristen M. Hege, M.D. to Its Board of Directors
February 12, 2025
·
3 min read
Press Releases
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
February 12, 2025
·
11 min read
Press Releases
BostonGene Collaborates with BeiGene to Advance Biomarker Discovery in Mantle Cell Lymphoma
February 12, 2025
·
2 min read
Press Releases
Levee Medical® Secures $10 Million in Oversubscribed Series B Funding
February 12, 2025
·
2 min read
Press Releases
Preprint from Northwestern University Highlights Complementary Proteomic Analysis of Interleukin-6 Using Next-Generation Protein Sequencing™ and Mass Spectrometry
February 12, 2025
·
5 min read
Press Releases
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
February 12, 2025
·
6 min read
Press Releases
Edwards Lifesciences Reports Fourth Quarter Results
February 12, 2025
·
19 min read
Previous
2 of 14
Next
